160.49
+1.97(+1.24%)
Currency In USD
| Previous Close | 158.52 |
| Open | 157.78 |
| Day High | 161.44 |
| Day Low | 156.13 |
| 52-Week High | 219.34 |
| 52-Week Low | 107.5 |
| Volume | 136,550 |
| Average Volume | 242,912 |
| Market Cap | 4.62B |
| PE | 90.16 |
| EPS | 1.78 |
| Moving Average 50 Days | 179.04 |
| Moving Average 200 Days | 179.4 |
| Change | 1.97 |
If you invested $1000 in Krystal Biotech, Inc. (KRYS) since IPO date, it would be worth $15,083.65 as of December 27, 2024 at a share price of $160.49. Whereas If you bought $1000 worth of Krystal Biotech, Inc. (KRYS) shares 5 years ago, it would be worth $2,668.16 as of December 27, 2024 at a share price of $160.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Dec 18, 2024 1:00 PM GMT
Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
GlobeNewswire Inc.
Dec 12, 2024 1:00 PM GMT
Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluated to date
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
GlobeNewswire Inc.
Dec 09, 2024 9:15 PM GMT
CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology